TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07640737: AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)

Sponsor: Aurigene Discovery Technologies Limited · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,247,400

Rescue Site Savings

+$831,600

Unlock Full NCT07640737 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07640737 Rescue Dossier →